Novartis wraps up Eon

Executive Summary

Sandoz, Hexall AG and newly added Eon Labs are expected to generate more than 80 generic approvals per year, the parent company says July 21. Novartis completed the acquisition of Eon two days after receiving clearance from the Federal Trade Commission. Under a proposed consent order with FTC, Novartis agreed to divest three generic drugs - Sandoz' muscle relaxant orphenadrine and tuberculosis treatment rifampin, and Eon's antidepressant desipramine - to Amide Pharmaceuticals. "The Pink Sheet" (1July 18, In Brief) incorrectly identified desipramine as a Sandoz drug and rifampin as an Eon product...